ZA200006381B - Attenuated mutants of salmonella which constitutively express the vi antigen. - Google Patents

Attenuated mutants of salmonella which constitutively express the vi antigen. Download PDF

Info

Publication number
ZA200006381B
ZA200006381B ZA200006381A ZA200006381A ZA200006381B ZA 200006381 B ZA200006381 B ZA 200006381B ZA 200006381 A ZA200006381 A ZA 200006381A ZA 200006381 A ZA200006381 A ZA 200006381A ZA 200006381 B ZA200006381 B ZA 200006381B
Authority
ZA
South Africa
Prior art keywords
mutant
vaccine
cvd
salmonella
supra
Prior art date
Application number
ZA200006381A
Other languages
English (en)
Inventor
Fernando R Noriega
Marcelo Sztein
Myron M Levine
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of ZA200006381B publication Critical patent/ZA200006381B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/879—Salmonella

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200006381A 1998-05-13 2000-11-07 Attenuated mutants of salmonella which constitutively express the vi antigen. ZA200006381B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/076,761 US6190669B1 (en) 1998-05-13 1998-05-13 Attenuated mutants of salmonella which constitutively express the Vi antigen

Publications (1)

Publication Number Publication Date
ZA200006381B true ZA200006381B (en) 2002-02-07

Family

ID=22134022

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200006381A ZA200006381B (en) 1998-05-13 2000-11-07 Attenuated mutants of salmonella which constitutively express the vi antigen.

Country Status (16)

Country Link
US (1) US6190669B1 (fr)
EP (1) EP1076566B1 (fr)
JP (1) JP4363782B2 (fr)
AT (1) ATE333285T1 (fr)
AU (1) AU754795B2 (fr)
CA (1) CA2328056C (fr)
DE (1) DE69932425T2 (fr)
DK (1) DK1076566T3 (fr)
ES (1) ES2268864T3 (fr)
HU (1) HUP0101747A3 (fr)
MX (1) MXPA00011075A (fr)
NO (1) NO20005672L (fr)
NZ (1) NZ508110A (fr)
PL (1) PL192378B1 (fr)
WO (1) WO1999058146A1 (fr)
ZA (1) ZA200006381B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3633933B2 (ja) * 1992-07-31 2005-03-30 アカンビス、リサーチ、リミテッド 弱毒化細菌における組換え融合タンパク質の発現
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
ATE318924T1 (de) * 1998-12-04 2006-03-15 Univ Manitoba Zwei-schritte-verfahren zur impfung gegen chlamydia
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
US7026155B2 (en) * 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
MXPA00012796A (es) * 1999-12-28 2002-05-23 Akzo Nobel Nv Vacuna de salmonella.
PL359293A1 (en) * 2000-04-20 2004-08-23 University Of Maryland, Baltimore Isolation and characterization of the csa operon (etec-cs4 pili) and methods of using same
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US7541043B2 (en) 2002-01-16 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Vaccine for protection against Shigella sonnei disease
WO2004001020A2 (fr) * 2002-06-19 2003-12-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Procedes et moyens permettant de favoriser l'absorption intestinale
CA2506031A1 (fr) * 2002-11-15 2004-06-03 Vib Vzw Souche de lactobacillus automone comprenant une mutation du gene thya et applications therapeutiques associees
EP1941024B1 (fr) * 2005-10-28 2013-07-31 University of Maryland, Baltimore Salmonella enterica sérotype paratyphi a atténué et procédés de son utilisation
US8137930B2 (en) 2005-10-28 2012-03-20 University Of Maryland, Baltimore Attenuated Salmonella enterica serovar paratyphi A and uses thereof
WO2007062371A2 (fr) * 2005-11-23 2007-05-31 University Of Maryland, Baltimore Vaccin de vecteur vivant et ses utilisations
AU2006319216B2 (en) 2005-11-29 2012-09-13 Intrexon Actobiotics Nv Induction of mucosal tolerance to antigens
BRPI0621490A2 (pt) * 2006-03-20 2011-12-13 Univ Bruxelles cepa mutante atenuada de uma bactéria infectante de espécies veterinárias, vacina para imunização de espécies veterinárias contra uma infecção bacteriana, método para imunizar uma espécie veterinária contra uma infecção bacteriana, uso de uma cepa mutante atenuada e método para distinção sorológica entre animais vacinados e animais infectados por uma cepa alelo-selvagem
EP2004802A1 (fr) * 2006-03-20 2008-12-24 Vrije Universiteit Brussel Vaccin vivant atténué contre la salmonella
EP2857038B1 (fr) 2006-09-18 2019-04-10 The Board of Trustees of the University of Arkansas Compositions et procédés d'amélioration des réponses immunitaires
EP3351268B1 (fr) 2007-01-25 2020-08-05 Intrexon Actobiotics NV Traitement d'une maladie immunitaire par l'administration mucosale d'antigènes
US20110020399A1 (en) * 2007-04-16 2011-01-27 University Of Maryland, Baltimore Vaccines and Immunomodulatory Therapies for Tularemia
US9125854B2 (en) * 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT2214701T (pt) 2007-11-01 2016-11-02 Univ Guelph Composições e métodos de potenciar respostas imunes a eimeria
WO2010036226A1 (fr) * 2008-09-26 2010-04-01 George Nelson Méthode de traitement de la polyarthrite rhumatoïde, des tremblements/de la maladie de parkinson et de la sclérose en plaques
WO2010141143A2 (fr) * 2009-04-21 2010-12-09 Vivocure, Inc. Souches bactériennes avirulentes génétiquement modifiées et utilisations dans des traitements médicaux
NO2525817T3 (fr) 2010-01-21 2018-01-06
BR112012031211A2 (pt) 2010-06-09 2018-01-30 Univ Arkansas métodos e vacina para reduzir a infecção causada pelo campylobacter
WO2013126622A1 (fr) * 2012-02-24 2013-08-29 President And Fellows Of Harvard College Procédés de présentation de polypeptides et leurs utilisations
EP2956165B1 (fr) 2013-02-14 2019-09-11 The Board of Trustees of the University of Arkansas Compositions et procédés pour renforcer des réponses immunitaires vis-à-vis d'eimeria ou limiter une infection par eimeria
CN105142653B (zh) 2013-03-15 2019-11-15 阿肯色大学评议会 增强对肠病原体免疫应答的组合物和方法
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso
KR20240054373A (ko) * 2021-09-10 2024-04-25 리젠츠 오브 더 유니버시티 오브 미네소타 종양의 비독성 콜로니화를 위해 조작된 살모넬라

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US5783196A (en) 1996-04-09 1998-07-21 University Of Maryland At Baltimore Gua mutants of shigella spp. and vaccines containing the same

Also Published As

Publication number Publication date
AU3740599A (en) 1999-11-29
EP1076566A4 (fr) 2005-01-05
PL344593A1 (en) 2001-11-05
HUP0101747A2 (hu) 2001-09-28
PL192378B1 (pl) 2006-10-31
NO20005672L (no) 2001-01-15
ATE333285T1 (de) 2006-08-15
NZ508110A (en) 2002-10-25
AU754795B2 (en) 2002-11-28
CA2328056A1 (fr) 1999-11-18
WO1999058146A1 (fr) 1999-11-18
EP1076566A1 (fr) 2001-02-21
ES2268864T3 (es) 2007-03-16
MXPA00011075A (es) 2002-04-24
NO20005672D0 (no) 2000-11-10
DE69932425T2 (de) 2007-03-08
HUP0101747A3 (en) 2002-03-28
JP4363782B2 (ja) 2009-11-11
EP1076566B1 (fr) 2006-07-19
US6190669B1 (en) 2001-02-20
DK1076566T3 (da) 2006-11-13
DE69932425D1 (de) 2006-08-31
JP2002514398A (ja) 2002-05-21
CA2328056C (fr) 2010-07-06

Similar Documents

Publication Publication Date Title
AU754795B2 (en) Attenuated mutants of salmonella which constitutively express the Vi antigen
Cardenas et al. Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens
JP4583607B2 (ja) 感染症の治療のための弱毒化微生物
JP3004049B2 (ja) 病原性のないｐｈｏＰ型微生物を含有するワクチン
EP0368966B1 (fr) Nouveaux vaccins vivants reversibles de shigella
US7700104B2 (en) Attenuated Salmonella SP12 mutants as antigen carriers
US7083794B2 (en) Recombinant vaccines comprising immunogenic attenuated bacteria having RpoS positive phenotype
CA2099841C (fr) Expression de proteines recombinantes dans des bacteries attenuees
EP0672116B1 (fr) Mutants de deletion utilises en tant que vaccins contre le cholera
Khan et al. Salmonella typhi and S. typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella Pathogenicity Island-2 (SPI-2) genes as vaccines and vectors
JP6329544B2 (ja) 新規生弱毒化赤痢菌属（Ｓｈｉｇｅｌｌａ）ワクチン
Dougan et al. Live bacterial vaccines and their application as carriers for foreign antigens
US20070116725A1 (en) Live Attenuated Samonella Strains for Producing Monovalent or Multivalent Vaccines
AU2002339623A1 (en) Live attenuated salmonella strains for producing vaccines
Sory et al. Yersinia enterocolitica O: 9 as a potential live oral carrier for protective antigens
US5874088A (en) Deletion mutants of cholera vaccines expressing heterologous antigens
Tacket et al. Cholera vaccines
US5783196A (en) Gua mutants of shigella spp. and vaccines containing the same
WO1991018092A1 (fr) Bacille salmonella typhi tolerant les acides, mutants aro doubles de ce bacille et utilisation de ce bacille comme vaccin administre par voie buccale contre la fievre typhoide
Stevenson et al. Intranasal immunisation against tetanus with an attenuated Bordetella bronchiseptica vector expressing FrgC: improved immunogenicity using a Bvg-regulated promoter to express FrgC
CZ20003851A3 (cs) Oslabený mutovaný kmen Salmonella a vakcína proti břišnímu tyfu
Based Progress in the Development of
Hormaeche¹ et al. Department of Biochemistry2, Imperial College of Science, Technology and Medicine
Freytag Effect of gene location on in vitro and in vivo stability, immunogenicity and expression of foreign antigens in bacterial vaccine fectors